1. Home
  2. SKE vs ADMA Comparison

SKE vs ADMA Comparison

Compare SKE & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$34.08

Market Cap

3.8B

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$10.82

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKE
ADMA
Founded
1979
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
2.4B
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
SKE
ADMA
Price
$34.08
$10.82
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$28.00
AVG Volume (30 Days)
685.2K
9.8M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.60
Revenue
N/A
$42,219,783.00
Revenue This Year
N/A
$27.46
Revenue Next Year
$37,573.35
$22.11
P/E Ratio
N/A
$18.35
Revenue Growth
N/A
43.85
52 Week Low
$11.11
$7.21
52 Week High
$38.77
$25.67

Technical Indicators

Market Signals
Indicator
SKE
ADMA
Relative Strength Index (RSI) 62.63 44.50
Support Level $30.44 $7.21
Resistance Level $35.09 $16.48
Average True Range (ATR) 1.46 0.47
MACD 0.45 0.38
Stochastic Oscillator 91.49 87.29

Price Performance

Historical Comparison
SKE
ADMA

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: